RETA demonstrated the most cecal content with 6.3-fold greater mass than Veh, and SEMA had half the mass found in RETA (Supplementary Fig
Additionally, it has received approval for the prevention and management of cardiovascular events in adults with type 2 diabetes and also those having existing cardiovascular disease
But because food is staying in your stomach and digestive system for an extended period of time and the impact on certain receptors in the brain, it raises your risk for the most common gastrointestinal GLP-1 side effects, like nausea, vomiting, diarrhea, and constipation
In SUSTAIN 3, 34% of patients achieved target with once-weekly semaglutide 1.0 mg, compared with 13% for exenatide ER, while in SUSTAIN 7, 33% and 48% achieved target with once-weekly semaglutide 0.5 mg and 1.0 mg, respectively, compared with 16% with dulaglutide 0.75 mg and 23% with dulaglutide 1.5 mg (Table 1)